Xeris Biopharma (XERS) Financials

Xeris Biopharma logo
$16.77 +0.07 (+0.42%)
As of 01:33 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for Xeris Biopharma

Annual Income Statements for Xeris Biopharma

This table shows Xeris Biopharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-91 -123 -95 -62 -55 0.55
Consolidated Net Income / (Loss)
-91 -123 -95 -62 -55 0.55
Net Income / (Loss) Continuing Operations
-91 -123 -95 -62 -55 0.55
Total Pre-Tax Income
-91 -123 -96 -64 -57 0.55
Total Operating Income
-84 -115 -82 -44 -34 25
Total Gross Profit
11 36 88 135 166 249
Total Revenue
20 50 110 164 203 292
Operating Revenue
20 50 110 164 203 292
Total Cost of Revenue
9.05 13 23 29 37 43
Operating Cost of Revenue
9.05 13 23 29 37 43
Total Operating Expenses
95 151 170 179 200 224
Selling, General & Admin Expense
74 126 138 146 163 182
Research & Development Expense
21 25 21 22 26 31
Amortization Expense
0.00 0.55 11 11 11 11
Total Other Income / (Expense), net
-7.70 -7.57 -14 -19 -23 -24
Interest Expense
11 7.18 15 29 33 29
Interest & Investment Income
2.97 0.31 2.58 4.75 5.32 4.74
Other Income / (Expense), net
-0.01 -0.70 -1.40 5.20 4.40 0.00
Income Tax Expense
-0.11 0.00 -1.42 -1.25 -2.27 0.00
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)
0.01 0.04 -0.01 0.00 0.00 0.00
Basic Earnings per Share
($2.14) ($1.55) ($0.70) ($0.45) ($0.37) $0.00
Weighted Average Basic Shares Outstanding
42.64M 79.03M 135.63M 137.67M 146.77M 160.43M
Diluted Earnings per Share
($2.14) ($1.55) ($0.70) ($0.45) ($0.37) $0.00
Weighted Average Diluted Shares Outstanding
42.64M 79.03M 135.63M 137.67M 146.77M 172.74M
Weighted Average Basic & Diluted Shares Outstanding
42.64M 79.03M 137.29M 140.45M 153.94M 172.43M

Quarterly Income Statements for Xeris Biopharma

This table shows Xeris Biopharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-19 -15 -16 -5.13 -9.22 -1.93 0.62 11 2.23 -31 11
Consolidated Net Income / (Loss)
-19 -15 -16 -5.11 -9.22 -1.93 0.62 11 2.23 -31 11
Net Income / (Loss) Continuing Operations
-19 -15 -16 -5.11 -9.22 -1.93 0.62 11 2.23 -31 11
Total Pre-Tax Income
-19 -14 -19 -5.11 -9.22 -1.93 0.62 11 2.23 -31 11
Total Operating Income
-14 -8.19 -13 1.68 -3.09 4.48 6.73 17 7.92 5.17 17
Total Gross Profit
35 40 41 51 51 60 63 75 73 80 95
Total Revenue
41 48 54 60 60 72 74 86 83 92 107
Operating Revenue
41 48 54 60 60 72 74 86 83 92 107
Total Cost of Revenue
5.97 7.79 14 9.48 8.73 12 11 11 11 13 12
Operating Cost of Revenue
5.97 7.79 14 9.48 8.73 12 11 11 11 13 12
Total Operating Expenses
49 48 54 49 54 55 57 58 65 74 78
Selling, General & Admin Expense
38 40 45 40 44 44 46 48 53 61 64
Research & Development Expense
7.82 5.76 5.89 6.09 7.75 8.06 7.48 7.87 8.78 11 11
Amortization Expense
2.71 2.71 2.71 2.71 2.71 2.71 2.71 2.71 2.71 2.71 2.71
Total Other Income / (Expense), net
-4.43 -6.07 -6.17 -6.79 -6.13 -6.41 -6.11 -5.69 -5.68 -36 -5.63
Interest Expense
9.72 7.96 7.79 7.70 7.31 7.36 7.27 7.15 6.88 38 6.46
Interest & Investment Income
1.92 1.29 1.20 0.91 1.18 0.95 1.16 1.46 1.20 1.46 0.83
Income Tax Expense
0.31 0.75 -3.32 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Basic Earnings per Share
($0.14) ($0.10) ($0.11) ($0.02) ($0.06) ($0.01) $0.00 $0.07 $0.01 ($0.18) $0.06
Weighted Average Basic Shares Outstanding
140.51M 148.35M 148.99M 146.77M 152.45M 159.46M 163.65M 160.43M 170.52M 172.82M 180.94M
Diluted Earnings per Share
($0.14) ($0.10) ($0.11) ($0.02) ($0.06) ($0.01) $0.00 $0.07 $0.01 ($0.18) $0.06
Weighted Average Diluted Shares Outstanding
140.51M 148.35M 148.99M 146.77M 152.45M 159.46M 177.62M 172.74M 177.63M 172.82M 189.92M
Weighted Average Basic & Diluted Shares Outstanding
148.26M 149.00M 149.08M 153.94M 160.16M 161.48M 165.92M 172.43M 172.64M 182.32M 182.70M

Annual Cash Flow Statements for Xeris Biopharma

This table details how cash moves in and out of Xeris Biopharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
18 30 59 -55 4.07 39
Net Cash From Operating Activities
-81 -96 -103 -47 -37 29
Net Cash From Continuing Operating Activities
-81 -96 -103 -47 -37 29
Net Income / (Loss) Continuing Operations
-91 -123 -95 -62 -55 0.55
Consolidated Net Income / (Loss)
-91 -123 -95 -62 -55 0.55
Depreciation Expense
1.47 1.33 1.40 1.49 1.23 1.31
Amortization Expense
1.06 1.92 13 13 14 15
Non-Cash Adjustments To Reconcile Net Income
16 17 17 18 24 37
Changes in Operating Assets and Liabilities, net
-8.34 6.53 -39 -16 -21 -25
Net Cash From Investing Activities
-27 98 34 -6.00 4.88 -0.70
Net Cash From Continuing Investing Activities
-27 98 34 -6.00 4.88 -0.70
Purchase of Property, Plant & Equipment
-0.38 -1.09 -0.52 -2.26 -0.87 -0.70
Purchase of Investments
-102 -43 0.00 -44 -34 0.00
Sale and/or Maturity of Investments
75 104 35 40 40 0.00
Net Cash From Financing Activities
126 27 127 -1.61 36 11
Net Cash From Continuing Financing Activities
126 27 127 -1.61 36 11
Repayment of Debt
-31 0.00 -49 -1.19 -12 0.00
Issuance of Debt
95 0.00 146 0.00 50 0.00
Issuance of Common Equity
67 28 31 0.55 1.24 11
Other Financing Activities, net
0.07 -0.34 -0.46 -0.98 -3.25 0.70
Cash Interest Paid
4.56 7.29 11 28 27 27

Quarterly Cash Flow Statements for Xeris Biopharma

This table details how cash moves in and out of Xeris Biopharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-4.76 -5.09 1.53 12 -13 0.85 32 19 0.71 10.00 9.34
Net Cash From Operating Activities
-20 -10 -8.31 1.98 -10 0.18 18 20 9.87 8.26 35
Net Cash From Continuing Operating Activities
-20 -10 -8.31 1.98 -10 0.18 18 20 9.87 8.26 35
Net Income / (Loss) Continuing Operations
-19 -15 -16 -5.11 -9.22 -1.93 0.62 11 2.23 -31 11
Consolidated Net Income / (Loss)
-19 -15 -16 -5.11 -9.22 -1.93 0.62 11 2.23 -31 11
Depreciation Expense
0.33 0.28 0.31 0.31 0.32 0.33 0.34 0.34 0.34 0.32 0.32
Amortization Expense
3.28 3.38 3.43 3.57 3.67 3.66 3.69 3.73 3.76 3.79 3.81
Non-Cash Adjustments To Reconcile Net Income
1.97 6.25 5.48 10 6.36 11 19 0.73 9.72 47 19
Changes in Operating Assets and Liabilities, net
-6.89 -5.26 -1.78 -7.05 -11 -13 -4.82 4.28 -6.18 -12 1.28
Net Cash From Investing Activities
-20 4.60 9.91 10 -0.01 -0.28 -0.07 -0.33 -0.33 -0.21 -0.16
Net Cash From Continuing Investing Activities
-20 4.60 9.91 10 -0.01 -0.28 -0.07 -0.33 -0.33 -0.21 -0.16
Net Cash From Financing Activities
35 0.66 -0.08 0.40 -3.14 0.94 14 -0.27 -8.84 1.94 -26
Net Cash From Continuing Financing Activities
35 0.66 -0.08 0.40 -3.14 0.94 14 -0.27 -8.84 1.94 -26
Issuance of Common Equity
- - - 0.53 0.00 - 9.17 0.69 7.33 1.59 0.05
Other Financing Activities, net
-2.98 -0.05 -0.08 -0.14 -3.14 0.11 4.68 -0.96 -16 0.36 -2.95
Cash Interest Paid
1.50 6.82 13 6.02 0.00 13 7.08 6.95 5.35 5.38 6.78

Annual Balance Sheets for Xeris Biopharma

This table presents Xeris Biopharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
159 304 345 323 323 384
Total Current Assets
152 143 187 156 168 240
Cash & Equivalents
38 67 122 67 72 111
Accounts Receivable
6.88 17 31 39 40 51
Inventories, net
8.35 18 25 39 48 69
Prepaid Expenses
3.20 4.59 9.29 5.78 7.45 9.55
Plant, Property, & Equipment, net
6.71 6.63 5.52 5.97 5.56 4.95
Total Noncurrent Assets
0.23 155 152 160 150 138
Goodwill
0.00 23 23 23 23 23
Intangible Assets
0.00 131 121 110 99 88
Other Noncurrent Operating Assets
0.23 0.83 8.72 28 28 27
Total Liabilities & Shareholders' Equity
159 304 345 323 323 384
Total Liabilities
125 209 299 329 353 370
Total Current Liabilities
28 79 74 95 100 110
Accounts Payable
3.12 8.92 4.61 12 2.29 3.08
Accrued Expenses
25 68 65 60 76 95
Other Current Liabilities
0.32 1.99 4.24 4.66 7.17 11
Total Noncurrent Liabilities
97 130 226 234 252 260
Long-Term Debt
87 88 187 191 217 220
Other Noncurrent Operating Liabilities
3.53 30 35 41 35 40
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
34 95 45 -6.78 -30 14
Total Preferred & Common Equity
34 95 45 -6.78 -30 14
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
34 95 45 -6.78 -30 14
Common Stock
371 555 600 610 642 685
Retained Earnings
-337 -460 -555 -617 -672 -671
Accumulated Other Comprehensive Income / (Loss)
0.01 -0.03 -0.02 -0.03 -0.03 -0.03

Quarterly Balance Sheets for Xeris Biopharma

This table presents Xeris Biopharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
329 328 337 332 321 315 335 370 392 412 423
Total Current Assets
156 158 173 170 163 163 186 224 252 275 289
Cash & Equivalents
46 46 63 58 59 58 59 92 112 122 131
Accounts Receivable
30 46 37 42 41 46 53 54 56 58 69
Inventories, net
37 38 41 43 45 53 67 67 74 81 77
Prepaid Expenses
8.31 7.97 7.64 7.36 7.14 6.03 5.96 11 9.40 14 13
Plant, Property, & Equipment, net
6.55 6.19 5.78 5.83 5.61 5.26 5.28 4.95 5.03 4.83 4.64
Total Noncurrent Assets
166 164 158 156 153 147 144 141 135 132 129
Goodwill
23 23 23 23 23 23 23 23 23 23 23
Intangible Assets
115 112 107 104 102 96 94 91 85 83 80
Other Noncurrent Operating Assets
28 28 28 28 28 28 27 28 27 27 27
Total Liabilities & Shareholders' Equity
329 328 337 332 321 315 335 370 392 412 423
Total Liabilities
315 324 346 351 349 351 354 371 379 422 374
Total Current Liabilities
80 87 73 75 91 95 95 116 119 190 134
Accounts Payable
12 12 7.09 5.80 7.45 6.35 9.46 6.53 11 9.34 8.04
Accrued Expenses
48 54 37 40 62 70 78 101 51 58 116
Other Current Liabilities
3.65 3.49 28 30 6.72 6.27 7.79 8.84 56 58 10
Total Noncurrent Liabilities
235 237 273 276 258 256 259 255 260 232 240
Long-Term Debt
188 190 230 230 216 218 219 219 221 189 190
Other Noncurrent Operating Liabilities
44 44 40 42 42 38 40 35 39 43 50
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
14 3.87 -9.18 -19 -28 -35 -19 -0.86 13 -9.73 49
Total Preferred & Common Equity
14 3.87 -9.18 -19 -28 -35 -19 -0.86 13 -9.73 49
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
14 3.87 -9.18 -19 -28 -35 -19 -0.86 13 -9.73 49
Common Stock
605 608 627 632 638 646 664 682 682 690 738
Retained Earnings
-591 -604 -636 -651 -667 -681 -683 -682 -669 -700 -689
Accumulated Other Comprehensive Income / (Loss)
-0.08 -0.05 -0.04 -0.03 -0.02 -0.03 -0.02 -0.03 -0.02 -0.01 -0.01

Annual Metrics And Ratios for Xeris Biopharma

This table displays calculated financial ratios and metrics derived from Xeris Biopharma's official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
- - - - - 165,924,289.00
DEI Adjusted Shares Outstanding
- - - - - 165,924,289.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - 0.00
Growth Metrics
- - - - - -
Profitability Metrics
- - - - - -
Net Operating Profit after Tax (NOPAT)
-58 -81 -57 -31 -24 25
Return On Investment Capital (ROIC_SIMPLE)
- - -24.70% -15.16% -11.63% 10.64%
Earnings before Interest and Taxes (EBIT)
-84 -116 -83 -39 -29 25
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-81 -113 -69 -25 -14 41
Valuation Ratios
- - - - - -
Leverage & Solvency
- - - - - -
Liquidity Ratios
- - - - - -
Cash Flow Metrics
- - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -174 -87 -51 -24 33
Efficiency Ratios
- - - - - -
Capital & Investment Metrics
- - - - - -
Invested Capital
-13 81 110 131 131 123
Increase / (Decrease) in Invested Capital
0.00 94 29 21 0.06 -7.89
Book Value per Share
$0.79 $0.76 $0.33 ($0.05) ($0.20) $0.08
Tangible Book Value per Share
$0.79 ($0.47) ($0.72) ($1.01) ($1.02) ($0.59)
Total Capital
121 183 232 203 202 234
Total Debt
87 88 187 210 232 220
Total Long-Term Debt
87 88 187 191 217 220
Net Debt
-47 -14 65 138 160 109
Capital Expenditures (CapEx)
0.38 1.09 0.52 2.26 0.87 0.70
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-9.78 -39 -8.77 7.73 11 20
Debt-free Net Working Capital (DFNWC)
124 64 113 80 82 131
Net Working Capital (NWC)
124 64 113 61 67 131
Net Nonoperating Expense (NNE)
33 42 37 31 31 24
Net Nonoperating Obligations (NNO)
-47 -14 65 138 160 109
Total Depreciation and Amortization (D&A)
2.53 3.25 14 14 15 16
Earnings Adjustments
- - - - - -
Adjusted Basic Earnings per Share
$0.00 ($1.55) ($0.70) ($0.45) ($0.37) $0.00
Adjusted Weighted Average Basic Shares Outstanding
0.00 135.52M 135.63M 137.67M 146.77M 160.43M
Adjusted Diluted Earnings per Share
$0.00 ($1.55) ($0.70) ($0.45) ($0.37) $0.00
Adjusted Weighted Average Diluted Shares Outstanding
0.00 135.52M 135.63M 137.67M 146.77M 172.74M
Adjusted Basic & Diluted Earnings per Share
$0.00 ($1.55) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 79.03M 137.29M 140.45M 153.94M 172.43M
Normalized Net Operating Profit after Tax (NOPAT)
-58 -81 -57 -31 -24 17
Debt Service Ratios
- - - - - -
Payout Ratios
- - - - - -

Quarterly Metrics And Ratios for Xeris Biopharma

This table displays calculated financial ratios and metrics derived from Xeris Biopharma's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
- - - - - - - 165,924,289.00 172,431,290.00 172,642,055.00 182,320,306.00
DEI Adjusted Shares Outstanding
- - - - - - - 165,924,289.00 172,431,290.00 172,642,055.00 182,320,306.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - 0.07 0.01 -0.18 0.06
Growth Metrics
- - - - - - - - - - -
Revenue Growth
22.42% 26.46% 12.31% 35.39% 47.94% 48.84% 37.06% - 38.27% 28.74% 44.16%
EBITDA Growth
15.17% 66.55% -2,462.46% 236.54% 112.34% 315.97% 223.17% - 1,239.46% 9.73% 95.51%
EBIT Growth
8.76% 50.15% -214.66% 121.78% 71.58% 159.11% 153.96% - 356.18% 15.42% 151.36%
NOPAT Growth
-7.29% 48.76% -162.43% 117.06% 78.31% 154.75% 174.58% - 465.97% 15.42% 151.36%
Net Income Growth
-12.75% 24.38% -29.12% 61.81% 51.42% 87.15% 103.95% - 124.23% -1,513.12% 1,718.04%
EPS Growth
-16.67% 28.57% -22.22% 80.00% 57.14% 90.00% 100.00% - 116.67% -1,700.00% 0.00%
Operating Cash Flow Growth
22.33% 24.71% 43.16% -73.56% 50.59% 101.76% 321.94% - 198.40% 4,440.11% 92.44%
Free Cash Flow Firm Growth
85.27% 95.91% 106.60% 104.06% 36.55% -43.64% 309.13% - 615.67% 890.48% 174.95%
Invested Capital Growth
-2.44% -2.72% -8.41% 0.05% 1.51% 4.47% -4.90% - -10.07% -13.52% -15.43%
Revenue Q/Q Growth
-8.45% 18.28% 12.91% 10.74% 0.03% 19.00% 3.97% - -3.12% 10.79% 16.42%
EBITDA Q/Q Growth
-78.43% 46.09% -122.91% 163.68% -83.88% 843.81% 27.13% - -42.34% -22.68% 126.51%
EBIT Q/Q Growth
-40.95% 30.26% -64.49% 113.47% -283.93% 245.05% 50.18% - -52.81% -34.65% 227.06%
NOPAT Q/Q Growth
-44.75% 42.53% -57.48% 113.02% -284.04% 245.05% 114.54% - -52.81% -54.26% 367.23%
Net Income Q/Q Growth
-41.75% 20.94% -4.89% 67.51% -80.32% 79.09% 132.21% - -79.84% -1,492.17% 136.30%
EPS Q/Q Growth
-40.00% 28.57% -10.00% 81.82% -200.00% 83.33% 100.00% - -85.71% -1,900.00% 133.33%
Operating Cash Flow Q/Q Growth
-371.76% 49.03% 19.74% 123.78% -607.90% 101.81% 10,027.47% - -50.76% -16.28% 329.26%
Free Cash Flow Firm Q/Q Growth
75.88% 69.95% 263.45% -65.76% -477.40% 31.98% 565.54% - -12.31% 4.26% 61.93%
Invested Capital Q/Q Growth
2.57% -0.09% -0.36% -2.01% 4.07% 2.82% -9.30% - -0.40% -1.12% -11.31%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
85.31% 83.79% 74.95% 84.23% 85.48% 83.37% 85.22% - 87.28% 86.41% 88.41%
EBITDA Margin
-17.89% -8.16% -16.10% 9.26% 1.49% 11.83% 14.47% - 14.45% 10.09% 19.63%
Operating Margin
-35.05% -17.03% -23.76% 2.79% -5.14% 6.27% 9.05% - 9.52% 5.62% 15.78%
EBIT Margin
-26.76% -15.78% -22.98% 2.80% -5.14% 6.27% 9.05% - 9.52% 5.62% 15.78%
Profit (Net Income) Margin
-46.71% -31.22% -29.00% -8.51% -15.34% -2.70% 0.83% - 2.69% -33.77% 10.53%
Tax Burden Percent
101.64% 105.25% 82.56% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00% 100.00%
Interest Burden Percent
171.72% 188.00% 152.83% -304.35% 298.38% -43.02% 9.23% - 28.22% -601.22% 66.73%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-30.95% -15.91% -22.31% 3.04% -5.92% 7.87% 18.49% - 23.18% 10.10% 49.57%
ROIC Less NNEP Spread (ROIC-NNEP)
-38.13% -22.60% -26.72% -1.18% -10.41% 4.63% 14.27% - 19.13% -13.83% 43.54%
Return on Net Nonoperating Assets (RNNOA)
-458.31% 1,110.84% 332.00% 9.70% 73.92% -37.54% -141.66% - -242.93% 138.22% 169.44%
Return on Equity (ROE)
-489.26% 1,094.93% 309.69% 12.73% 68.00% -29.67% -123.18% - -219.75% 148.32% 219.01%
Cash Return on Invested Capital (CROIC)
-20.70% -16.40% -13.85% -18.05% -13.15% -9.39% 10.29% - 38.36% 34.11% 44.66%
Operating Return on Assets (OROA)
-13.94% -8.67% -13.27% 1.76% -3.51% 4.63% 6.97% - 8.48% 5.05% 14.65%
Return on Assets (ROA)
-24.33% -17.15% -16.75% -5.35% -10.47% -1.99% 0.64% - 2.39% -30.34% 9.77%
Return on Common Equity (ROCE)
-489.26% 1,094.93% 309.69% 12.73% 68.00% -29.67% -123.18% - -219.75% 148.32% 219.01%
Return on Equity Simple (ROE_SIMPLE)
701.69% 308.85% 222.83% 0.00% 128.32% 0.00% 0.00% - 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-9.97 -5.73 -9.03 1.18 -2.16 3.14 6.73 17 7.92 3.62 17
NOPAT Margin
-24.54% -11.92% -16.63% 1.96% -3.60% 4.39% 9.05% - 9.52% 3.93% 15.78%
Net Nonoperating Expense Percent (NNEP)
7.18% 6.68% 4.42% 4.22% 4.49% 3.24% 4.22% - 4.05% 23.93% 6.04%
Return On Investment Capital (ROIC_SIMPLE)
- - - 0.58% -1.11% 1.57% 3.08% 7.17% 3.38% 1.49% 7.09%
Cost of Revenue to Revenue
14.69% 16.21% 25.05% 15.77% 14.52% 16.63% 14.78% - 12.72% 13.59% 11.59%
SG&A Expenses to Revenue
94.44% 83.21% 82.86% 66.79% 73.22% 62.05% 62.46% - 63.93% 66.27% 59.79%
R&D to Revenue
19.25% 11.98% 10.85% 10.14% 12.90% 11.26% 10.06% - 10.57% 11.58% 10.31%
Operating Expenses to Revenue
120.36% 100.83% 98.71% 81.44% 90.62% 77.10% 76.17% - 77.76% 80.80% 72.63%
Earnings before Interest and Taxes (EBIT)
-11 -7.58 -12 1.68 -3.09 4.48 6.73 17 7.92 5.17 17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-7.27 -3.92 -8.74 5.56 0.90 8.47 11 21 12 9.29 21
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 76.87 0.00 35.73
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Price to Revenue (P/Rev)
1.81 1.84 2.27 2.49 3.80 3.04 4.94 - 3.18 4.08 4.73
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 83.29 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 1.20% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
3.38 3.63 4.39 5.09 7.46 6.48 11.36 - 9.06 12.37 16.77
Enterprise Value to Revenue (EV/Rev)
2.65 2.68 3.13 3.28 4.57 3.69 5.42 - 3.52 4.47 4.89
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 146.59 56.14 - 21.31 28.32 28.51
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 147.13 - 30.91 40.94 38.51
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 210.21 - 30.91 58.49 55.02
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 136.61 - 22.87 26.47 24.46
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 107.55 - 22.36 33.63 34.42
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
-25.14 -11.97 -8.17 -7.84 -6.54 -11.33 -254.90 - 17.00 -25.95 3.89
Long-Term Debt to Equity
-25.02 -11.95 -7.63 -7.33 -6.20 -11.33 -254.90 - 17.00 -19.40 3.89
Financial Leverage
12.02 -49.16 -12.42 -8.19 -7.10 -8.10 -9.93 - -12.70 -9.99 3.89
Leverage Ratio
31.53 -117.01 -26.53 -17.74 -14.72 -17.27 -23.69 - -31.99 -25.71 16.56
Compound Leverage Factor
54.14 -219.97 -40.55 53.99 -43.91 7.43 -2.19 - -9.03 154.58 11.05
Debt to Total Capital
104.14% 109.11% 113.95% 114.63% 118.05% 109.68% 100.39% - 94.45% 104.01% 79.55%
Short-Term Debt to Total Capital
0.46% 0.20% 7.42% 7.46% 6.14% 0.00% 0.00% - 0.00% 26.26% 0.00%
Long-Term Debt to Total Capital
103.68% 108.92% 106.54% 107.17% 111.90% 109.68% 100.39% - 94.45% 77.74% 79.55%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Common Equity to Total Capital
-4.14% -9.11% -13.95% -14.63% -18.05% -9.68% -0.39% - 5.55% -4.01% 20.45%
Debt to EBITDA
-9.86 -14.79 -9.64 -16.16 -37.08 35.32 8.54 - 4.25 4.77 3.00
Net Debt to EBITDA
-6.12 -9.82 -6.74 -11.17 -27.65 25.75 4.98 - 2.10 2.47 0.93
Long-Term Debt to EBITDA
-9.81 -14.77 -9.01 -15.11 -35.15 35.32 8.54 - 4.25 3.57 3.00
Debt to NOPAT
-7.33 -8.87 -7.32 -9.86 -14.59 -31.80 31.99 - 6.16 9.86 5.79
Net Debt to NOPAT
-4.55 -5.89 -5.12 -6.81 -10.88 -23.18 18.64 - 3.05 5.11 1.79
Long-Term Debt to NOPAT
-7.29 -8.85 -6.84 -9.21 -13.83 -31.80 31.99 - 6.16 7.37 5.79
Altman Z-Score
-1.35 -1.36 -1.45 -1.16 -0.64 -0.49 0.67 - 0.47 0.67 1.96
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
2.37 2.26 1.79 1.67 1.72 1.95 1.93 - 2.12 1.45 2.15
Quick Ratio
1.71 1.59 1.21 1.12 1.10 1.18 1.25 - 1.42 0.95 1.48
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-6.61 -1.99 3.25 1.11 -4.19 -2.85 13 25 22 23 37
Operating Cash Flow to CapEx
-12,379.88% -2,606.55% -9,545.98% 897.73% -77,161.54% 65.23% 25,960.56% - 3,036.92% 3,953.59% 0.00%
Free Cash Flow to Firm to Interest Expense
-0.68 -0.25 0.42 0.14 -0.57 -0.39 1.83 - 3.14 0.60 5.66
Operating Cash Flow to Interest Expense
-2.09 -1.30 -1.07 0.26 -1.37 0.02 2.54 - 1.43 0.22 5.49
Operating Cash Flow Less CapEx to Interest Expense
-2.11 -1.35 -1.08 0.23 -1.37 -0.01 2.53 - 1.39 0.21 5.49
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.52 0.55 0.58 0.63 0.68 0.74 0.77 - 0.89 0.90 0.93
Accounts Receivable Turnover
5.02 4.99 4.30 5.10 5.32 5.15 5.61 - 6.14 6.04 6.02
Inventory Turnover
0.84 0.93 1.02 0.85 0.85 0.79 0.73 - 0.70 0.61 0.64
Fixed Asset Turnover
27.95 29.30 31.76 35.22 40.31 44.26 50.41 - 61.18 66.30 76.85
Accounts Payable Turnover
3.07 4.26 4.35 5.32 5.89 5.73 5.88 - 4.99 4.79 6.38
Days Sales Outstanding (DSO)
72.71 73.10 84.84 71.55 68.67 70.83 65.07 - 59.49 60.48 60.63
Days Inventory Outstanding (DIO)
435.53 391.28 357.71 431.14 431.34 460.50 499.90 - 521.53 600.69 567.14
Days Payable Outstanding (DPO)
118.84 85.72 83.90 68.65 61.98 63.73 62.07 - 73.22 76.19 57.22
Cash Conversion Cycle (CCC)
389.41 378.67 358.66 434.04 438.02 467.59 502.90 - 507.79 584.98 570.56
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
134 134 134 131 136 140 127 123 122 121 107
Invested Capital Turnover
1.26 1.33 1.34 1.55 1.65 1.80 2.04 - 2.43 2.57 3.14
Increase / (Decrease) in Invested Capital
-3.36 -3.75 -12 0.06 2.03 5.99 -6.55 -7.89 -14 -19 -20
Enterprise Value (EV)
454 487 587 666 1,016 907 1,442 - 1,110 1,498 1,802
Market Capitalization
310 334 425 505 845 748 1,314 - 1,000 1,367 1,743
Book Value per Share
($0.07) ($0.13) ($0.19) ($0.20) ($0.23) ($0.12) ($0.01) $0.08 $0.08 ($0.06) $0.27
Tangible Book Value per Share
($0.99) ($0.99) ($1.03) ($1.02) ($1.00) ($0.85) ($0.71) ($0.59) ($0.55) ($0.67) ($0.30)
Total Capital
222 212 203 202 195 199 219 234 234 243 238
Total Debt
231 231 231 232 230 219 219 220 221 253 190
Total Long-Term Debt
230 230 216 217 218 219 219 220 221 189 190
Net Debt
143 153 162 160 171 159 128 109 109 131 59
Capital Expenditures (CapEx)
0.16 0.40 0.09 0.22 0.01 0.28 0.07 0.33 0.33 0.21 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
14 18 17 11 22 31 16 20 21 27 24
Debt-free Net Working Capital (DFNWC)
101 95 87 82 80 90 108 131 133 149 155
Net Working Capital (NWC)
100 95 72 67 68 90 108 131 133 85 155
Net Nonoperating Expense (NNE)
9.01 9.27 6.71 6.29 7.06 5.07 6.11 5.69 5.68 35 5.63
Net Nonoperating Obligations (NNO)
143 153 162 160 171 159 128 109 109 131 59
Total Depreciation and Amortization (D&A)
3.60 3.66 3.74 3.88 3.99 3.98 4.03 4.06 4.10 4.12 4.12
Debt-free, Cash-free Net Working Capital to Revenue
8.09% 9.76% 9.31% 5.27% 9.86% 12.65% 6.09% - 6.78% 8.12% 6.44%
Debt-free Net Working Capital to Revenue
59.07% 52.52% 46.35% 40.54% 36.12% 36.75% 40.51% - 42.27% 44.41% 42.03%
Net Working Capital to Revenue
58.47% 52.29% 38.31% 33.10% 30.74% 36.75% 40.51% - 42.27% 25.40% 42.03%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.14) ($0.10) ($0.11) ($0.02) ($0.06) ($0.01) $0.00 $0.07 $0.01 ($0.18) $0.06
Adjusted Weighted Average Basic Shares Outstanding
140.51M 148.35M 148.99M 146.77M 152.45M 159.46M 163.65M 160.43M 170.52M 172.82M 180.94M
Adjusted Diluted Earnings per Share
($0.14) ($0.10) ($0.11) ($0.02) ($0.06) ($0.01) $0.00 $0.07 $0.01 ($0.18) $0.06
Adjusted Weighted Average Diluted Shares Outstanding
140.51M 148.35M 148.99M 146.77M 152.45M 159.46M 177.62M 172.74M 177.63M 172.82M 189.92M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
148.26M 149.00M 149.08M 153.94M 160.16M 161.48M 165.92M 172.43M 172.64M 182.32M 182.70M
Normalized Net Operating Profit after Tax (NOPAT)
-9.97 -5.73 -9.03 1.18 -2.16 3.14 4.71 12 5.54 3.62 12
Normalized NOPAT Margin
-24.54% -11.92% -16.63% 1.96% -3.60% 4.39% 6.33% - 6.67% 3.93% 11.05%
Pre Tax Income Margin
-45.95% -29.66% -35.13% -8.51% -15.34% -2.70% 0.83% - 2.69% -33.77% 10.53%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-1.12 -0.95 -1.60 0.22 -0.42 0.61 0.93 - 1.15 0.14 2.62
NOPAT to Interest Expense
-1.03 -0.72 -1.16 0.15 -0.30 0.43 0.93 - 1.15 0.10 2.62
EBIT Less CapEx to Interest Expense
-1.14 -1.00 -1.61 0.19 -0.42 0.57 0.92 - 1.10 0.13 2.62
NOPAT Less CapEx to Interest Expense
-1.04 -0.77 -1.17 0.12 -0.30 0.39 0.92 - 1.10 0.09 2.62
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Xeris Biopharma’s recent statements show strong revenue growth and improving operating performance, but the company remains burdened by high interest costs, shareholder dilution and negative equity. The latest quarter also included restated prior-period figures, so investors should treat comparisons involving 2024 and 2025 with some caution.

  • Revenue growth has remained robust. Second-quarter revenue increased from $48.1 million in 2024 to $71.5 million in 2025 and $92.1 million in 2026. That represents approximately 29% year-over-year growth in Q2 2026 and more than a doubling from Q2 2022.
  • Gross margins have improved. Gross profit reached $79.6 million in Q2 2026, equal to an approximately 86.4% gross margin. This compares with margins of roughly 83.4% in Q2 2025 and 83.8% in Q2 2024.
  • Operating profitability has turned positive. Xeris reported $5.2 million of operating income in Q2 2026, following $7.9 million in Q1 2026 and $16.8 million in Q4 2025. The company had reported operating losses in Q1 and Q2 2024, indicating meaningful improvement in the core business.
  • Operating cash flow has improved substantially. Cash flow from operations was $8.3 million in Q2 2026 and $9.9 million in Q1 2026, compared with only $182,000 in Q2 2025 and negative operating cash flow in Q1 2025 and much of 2024.
  • Liquidity has strengthened over the broader period. Cash and equivalents rose to $121.7 million at June 30, 2026, from $58.4 million at March 31, 2025 and $57.6 million at June 30, 2024. Current assets of $274.8 million exceeded current liabilities of $189.6 million, producing a current ratio of approximately 1.45.
  • Recent cash generation is partly dependent on noncash adjustments. Q2 2026 operating cash flow benefited from $47.3 million of noncash reconciliation adjustments, while net income was a $31.1 million loss. This means the quality and sustainability of the cash-flow improvement should be monitored in subsequent quarters.
  • Inventory and receivables have increased alongside sales. Accounts receivable rose to $58.1 million and inventory reached $80.9 million in Q2 2026, up from $53.0 million and $67.3 million, respectively, in Q2 2025. These increases may support future growth, but they also tie up working capital.
  • Interest costs sharply reduced earnings. Q2 2026 interest expense surged to $37.7 million from $6.9 million in Q1 2026 and $7.4 million in Q2 2025. As a result, a $5.2 million operating profit became a $31.1 million net loss, or a loss of $0.18 per share.
  • Debt levels have increased. Short-term and long-term debt totaled approximately $252.6 million at June 30, 2026, compared with $221.2 million at March 31, 2026 and $218.6 million at June 30, 2025. Cash interest paid was $5.4 million in Q2 2026, adding pressure to cash generation.
  • Shareholder dilution and negative equity remain significant risks. Basic weighted-average shares increased to 172.8 million in Q2 2026 from 159.5 million in Q2 2025 and 148.3 million in Q2 2024. Total shareholders’ equity also fell to negative $9.7 million at June 30, 2026 from positive $13.0 million in Q1 2026, while retained earnings stood at negative $700.2 million.

Overall, the statements point to a business with improving revenue, margins and operating cash flow. However, the latest quarter’s large interest expense overwhelmed operating profits, and the return to negative equity highlights the company’s financial leverage. For investors, the key questions are whether operating cash flow can remain positive and whether Xeris can reduce financing costs without relying heavily on additional equity issuance.

11/17/26 01:34 PM ETAI Generated. May Contain Errors.

Xeris Biopharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Xeris Biopharma's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Xeris Biopharma's net income appears to be on an upward trend, with a most recent value of $554 thousand in 2025, compared with -$91.14 million in 2020. The previous period was -$54.84 million in 2024. View Xeris Biopharma's forecast to see where analysts expect Xeris Biopharma to go next.

Xeris Biopharma's total operating income in 2025 was $24.90 million, based on the following breakdown:
  • Total Gross Profit: $249.28 million
  • Total Operating Expenses: $224.38 million

Over the last 5 years, Xeris Biopharma's total revenue changed from $20.16 million in 2020 to $291.85 million in 2025, a change of 1,348.0%.

In the past 13 quarters, Xeris Biopharma's cash and equivalents has ranged from $46.14 million in Q3 2023 to $131.08 million in Q3 2026, and is currently $131.08 million as of their latest financial filing in Q3 2026.

Xeris Biopharma had total debt of $220.34 million at the end of 2025, a 5.1% decrease from 2024, and a 153.2% increase since 2020.

Over the last 5 years, Xeris Biopharma's book value per share changed from 0.79 in 2020 to 0.08 in 2025, a change of -89.6%.



Financial statements for NASDAQ:XERS last updated on 11/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners